Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
I propose a new authority category for the Pharmaceutical Benefits Scheme (PBS)--authority to prescribe only within a controlled trial. This would benefit both the PBS and the pharmaceutical companies, but the main winners would be the Australian population, who would obtain better value for money spent by the PBS. Drugs which show promise, but for which conclusive evidence of advantage over standard therapy is lacking, or drugs for new indications, could be prescribed within a randomised trial. PBS support would fund a substantial portion of the trial costs. This proposal would greatly boost local and international investment in Australian medical research.
Glasziou
P P
PP
Department of Social and Preventive Medicine, University of Queensland, Brisbane.
D001315:Australia; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000379:methods*; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D015507:Drugs, Investigational / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D016032:Randomized Controlled Trials as Topic / Q000191:economics*; D012109:Research Support as Topic
D015507:Drugs, Investigational